US › Healthcare

AIM ImmunoTech Inc (AIM)

US · Healthcare · Biotechnology

$0.26-0.38%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$22,000

Revenue YoY

+37.5%

Net profit

$-3.0M

Profit YoY

+18.4%

EPS

$-0.69

EPS estimate

$-0.37

Net margin

-13,740.9%

EPS came in at -0.69 against a street estimate of -0.37 — a miss of 86.5%.

Key statistics

Market cap

$7.0M

Forward P/E

2.0

P/B

3.31

Book value

$0.26

EPS (TTM)

$-4.31

52-week high

$3.00

52-week low

$0.21

50-day MA

$0.36

200-day MA

$0.93

Beta

1.20

Analyst view

Analysts rate AIM ImmunoTech Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $5.25.

Shareholding

Insiders

0.59%

Institutions

0.76%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for AIM ImmunoTech Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.